Trial Profile
A Prospective, multicenter study on the safety and efficacy of the Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir and Ribavirin regimen in patients with hepatitis C virus genotype 1b infection with compensated cirrhosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017